Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (REGN) — Form 144: Proposed sale of shares
AI-generated summary
Director Kathryn Guarini filed to propose the sale of 400 shares of Common stock with an aggregate market value of $360,000 through UBS Financial Services, Inc., following an exercise of stock options on October 30, 2026. The proposed sale is associated with a trading plan adopted on February 13, 2026.
Key facts
- Seller
- Guarini Kathryn
- Relationship
- Director
- Shares to sell
- 400
- Market value
- $360,000.00
- Approximate sale date
- Oct 30, 2026
- Broker
- UBS Financial Services, Inc.
- Acquired
- Oct 30, 2026 · Exercise of stock option
Rule 10b5-1 plan · adopted Feb 13, 2026
More REGN filings
- 144
Filed Oct 30, 2026
- 144
Filed Oct 30, 2026
- 10-Q
Filed Oct 30, 2026
- 8-K
Filed Oct 30, 2026
- 4
Filed Oct 15, 2026
- 144
Filed Oct 14, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.